Reference
Reference TypeLiterature
TitleThe enterovirus 71 procapsid binds neutralizing antibodies and rescues virus infection in vitro.
AuthorsKristin L Shingler; Javier O Cifuente; Robert E Ashley; Alexander M Makhov; James F Conway; Susan Hafenstein
AffiliationsDepartment of Medicine and Department of Microbiology and Immunology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA; Department of Structural Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; Department of Medicine and Department of Microbiology and Immunology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA shafenstein@hmc.psu.edu.
JournalJ Virol
Year2015
AbstractEnterovirus 71 (EV71) is responsible for seasonal outbreaks of hand, foot, and mouth disease in the Asia-Pacific region. The virus has the capability to cause severe disease and death, especially in young children. Although several vaccines are currently in clinical trials, no vaccines or therapeutics have been approved for use. Previous structural studies have revealed that two antigenically distinct capsid forms are produced in EV71-infected cells: an expanded empty capsid, sometimes called a procapsid, and the infectious virus. Specifically, an immunodominant epitope of EV71 that maps to the virus canyon is structurally different in the procapsid and virus. This structure-function study shows that the procapsid can sequester antibodies, thus enhancing EV71 infection in vitro. The results presented here suggest that, due to conformational differences between the EV71 procapsid and virus, the presence of the procapsid in natural virus infections should be considered in the future design of vaccines or therapeutics. IMPORTANCE: Enterovirus 71 (EV71) is responsible for seasonal outbreaks of hand, foot, and mouth disease in the Asia-Pacific region. The virus has the capability to cause severe disease and death, especially in young children. Although several vaccines are currently in clinical trials, no vaccines or therapeutics have been approved for use. Previous structural studies have revealed that two antigenically distinct capsid forms are produced in EV71-infected cells: an expanded empty capsid, sometimes called a procapsid, and the infectious virus. Specifically, an immunodominant epitope of EV71 that maps to the virus canyon is structurally different in the procapsid and virus. This structure-function study shows that the procapsid can sequester antibodies, thus enhancing EV71 infection in vitro. The results presented here suggest that, due to conformational differences between the EV71 procapsid and virus, the presence of the procapsid in natural virus infections should be considered in the future design of vaccines or therapeutics.In a picornavirus infection, both an infectious and a noninfectious empty capsid, sometimes referred to as a procapsid, are produced. It was novel to discover that the procapsid form of EV71 was expanded and antigenically distinct from the infectious virus. Previously, it had been supposed that this empty capsid was an off-pathway dead end or at best served for storage of pentameric subunits, which was later shown to be unlikely. It remains unexplained why picornaviruses evolutionarily conserve the wasteful production of so much noninfectious capsid. Here, we demonstrate that the EV71 procapsid has different antigenic properties than the infectious virus. Thus, the procapsid has the capacity to sequester neutralizing antibody and protect the virus, promoting or restoring a successful infection in vitro. This important observation should be considered in the future design and development of vaccines and therapeutics.
Curation Last Updated2023-08-18 22:02:40
Epitope
Epitope ID75418
Chemical TypeLinear peptide
Linear SequenceYPTFGEHKQEKDLEY
Source Molecule NameVP1 protein
Source OrganismEnterovirus A71 (Enterovirus 71)
Starting Position208
Ending Position222
Epitope Reference Details
Epitope Structure DefinesEpitope containing region/antigenic site
Epitope NameSP70 peptide of EV71
CommentsThe epitope sequence is from the cited reference: Foo et al. (2007) Virus Res 125(1): 61-68. [PMID: 17222936].
Location of Data in ReferenceCited reference
Immunization
Host OrganismMus musculus BALB/c
1st In Vivo Process
In Vivo Process TypeAdministration in vivo
1st Immunogen
Epitope RelationEpitope
Chemical TypeLinear peptide
Linear SequenceYPTFGEHKQEKDLEY
Source Molecule NameVP1 protein
Source OrganismEnterovirus A71 (Enterovirus 71)
Starting Position208
Ending Position222
Immunogen Details
Immunogen Reference NameSP70
Immunization Comments
Immunization CommentsImmunogen carrier: Protein conjugate: Keyhole limpet hemocyanin (Megathura crenulata). MAb 22A12 was obtained from SydLabs (Maiden, MA). Generation of the monoclonal antibody was previously described in the cited reference: Li et al. (2009) Biochem Biophys Res Commun 390: 1128-1128 [PMID: 19799860]. A cysteine residue was added at the C-terminal end of the peptide for conjugation. The peptide was chemically linked to the carrier protein mcKLH through a sulfide-linker. MAb 22A12 was obtained from SydLabs (Maiden, MA).
B Cell Assay
Qualitative MeasurementPositive
Method/Techniqueelectron microscopy
Measurement of3D structure
Assayed Antibody
Assayed Antibody Source MaterialPurified Immunoglobulin
Assayed Antibody Immunoglobulin DomainFab
Assayed Antibody Purification StatusMonoclonal
Assayed Antibody Name22A12
Assayed Antibody Heavy Chain TypeIgG
Antigen
Epitope RelationTaxonomic Child
Object TypeOrganism
OrganismHuman enterovirus 71 Subgenogroup C2
Antigen Details
Antigen Reference NameEV71 strain 1095/Shiga (genogroup C2)
Assay Reference Details
Assay Comments by IEDB CuratorThe epitope-specific Fab 22A12 was bound to the EV71 procapsid and the complex was reconstructed to 8.8-Å resolution. The central section of the resulting cryo-EM density map showed that the Fab variable-domain density was weaker overall than the capsid shell. These densities suggest that Fab 22A12 does not bind all 60 of the available binding sites on the surface of the icosahedron. The Fab density extends radially from the EV71 canyon region with very weak outer density corresponding to the Fab constant domain. The flexible hinge of Fab 22A12 likely allows movement of the constant domain, resulting in the weak cryo-EM density. The location of Fab 22A12 binding is similar to that of the receptor binding of other picornaviruses that require interaction with a host molecule in the virus canyon to initiate entry. Thus, the Fab binding suggested that antibody 22A12 might act to block receptor binding or mimic a canyon-binding receptor.
Location of Assay Data in ReferenceFigures 1, 2, 3, 4, 5 and PDB 3J93